{
  "source": "PA-Notification-Cystaran-Cystadrops.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1023-14\nProgram Prior Authorization/Notification\nMedication Cystaran® (cysteamine) ophthalmic solution, Cystadrops® (cysteamine)\nophthalmic solution\nP&T Approval Date 7/2013, 7/2014, 7/2015, 6/2016, 6/2017, 6/2018, 6/2019, 6/2020,\n10/2020, 11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nCystaran (cysteamine 0.44% ophthalmic solution) and Cystadrops (cysteamine 0.37%\nophthalmic solution) are cystine depleting agents indicated for the treatment of corneal\ncystine crystal accumulation in patients with cystinosis.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Cystaran or Cystadrops will be approved based on both of the following criteria:\na. Diagnosis of cystinosis\n-AND-\nb. Treatment of corneal cystine crystal accumulation\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Cystaran or Cystadrops will be approved based upon the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services Inc.\n1\n4. References:\n1. Cystaran [package insert]. Gaithersburg, MD: Leadiant Biosciences, Inc.; February 2022.\n2. Cystadrops [package insert]. Lebanon, NJ: Recordati Rare Diseases; September 2020.\nProgram Prior Authorization/Notification - Cystaran (cysteamine), Cystadrops\n(cysteamine)\nChange Control\n7/2013 New criteria.\n7/201",
    "ckage insert]. Lebanon, NJ: Recordati Rare Diseases; September 2020.\nProgram Prior Authorization/Notification - Cystaran (cysteamine), Cystadrops\n(cysteamine)\nChange Control\n7/2013 New criteria.\n7/2014 Annual review. No changes to the criteria.\n10/2014 Modification to implementation date\n7/2015 Annual review with no change to criteria.\n6/2016 Annual review with no change to criteria. Updated background and\nreferences.\n6/2017 Annual review with no change to criteria.\n6/2018 Annual review with no change to criteria.\n6/2019 Annual review with no change to criteria.\n6/2020 Annual review with no changes to criteria or reference.\n10/2020 Added Cystadrops to criteria.\n11/2021 Annual review. Updated references.\n11/2022 Annual review. Added state mandate language. Updated references.\n11/2023 Annual review. No changes.\n11/2024 Annual review. No changes.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}